Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)

AL Herrick, X Pan, S Peytrignet, M Lunt… - Annals of the …, 2017 - ard.bmj.com
Objectives The rarity of early diffuse cutaneous systemic sclerosis (dcSSc) makes
randomised controlled trials very difficult. We aimed to use an observational approach to …

Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study

S Peytrignet, CP Denton, M Lunt, R Hesselstrand… - …, 2018 - academic.oup.com
Objectives Our aim was to describe the burden of early dcSSc in terms of disability, fatigue
and pain in the European Scleroderma Observational Study cohort, and to explore …

Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study

AL Herrick, S Peytrignet, M Lunt, X Pan… - Annals of the …, 2018 - ard.bmj.com
Objectives Our aim was to use the opportunity provided by the European Scleroderma
Observational Study to (1) identify and describe those patients with early diffuse cutaneous …

A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of …

P Jobanputra, F Maggs, A Deeming, D Carruthers… - BMJ open, 2012 - bmjopen.bmj.com
Objective To compare adalimumab versus etanercept in patients with active rheumatoid
arthritis (RA) to test the hypothesis that adalimumab was not inferior to etanercept in terms of …

Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.

AL Herrick, S Peytrignet, M Lunt, X Pan… - 2018 - lilloa.univ-lille.fr
Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European
Scleroderma Observational Stu Page 1 563 Herrick AL, et al. Ann Rheum Dis 2018;77:563–570 …